Technical Analysis for FULC - Fulcrum Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 9.44 | -0.21% | -0.02 |
FULC closed down 0.21 percent on Thursday, March 28, 2024, on 82 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Boomer Sell Setup | Bearish Swing Setup | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Centerline Cross | Bearish | -0.21% | |
Crossed Above 50 DMA | Bullish | -0.21% | |
Inside Day | Range Contraction | -0.21% | |
Wide Bands | Range Expansion | -0.21% | |
Oversold Stochastic | Weakness | -0.21% |
Alert | Time |
---|---|
Possible NR7 | about 12 hours ago |
Possible Inside Day | about 12 hours ago |
Up 1% | about 13 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Down 2 % | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/07/2024
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Disability Disorders Dystrophy Muscular Dystrophy Hemoglobin Progressive Infancy Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Disability Disorders Dystrophy Muscular Dystrophy Hemoglobin Progressive Infancy Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.7 |
52 Week Low | 2.25 |
Average Volume | 676,614 |
200-Day Moving Average | 5.70 |
50-Day Moving Average | 9.26 |
20-Day Moving Average | 10.53 |
10-Day Moving Average | 9.82 |
Average True Range | 0.74 |
RSI (14) | 44.13 |
ADX | 33.53 |
+DI | 19.90 |
-DI | 21.33 |
Chandelier Exit (Long, 3 ATRs) | 11.49 |
Chandelier Exit (Short, 3 ATRs) | 11.06 |
Upper Bollinger Bands | 12.23 |
Lower Bollinger Band | 8.84 |
Percent B (%b) | 0.18 |
BandWidth | 32.21 |
MACD Line | -0.05 |
MACD Signal Line | 0.23 |
MACD Histogram | -0.2705 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.01 | ||||
Resistance 3 (R3) | 10.01 | 9.81 | 9.92 | ||
Resistance 2 (R2) | 9.81 | 9.67 | 9.82 | 9.88 | |
Resistance 1 (R1) | 9.63 | 9.58 | 9.53 | 9.63 | 9.85 |
Pivot Point | 9.43 | 9.43 | 9.39 | 9.44 | 9.43 |
Support 1 (S1) | 9.25 | 9.29 | 9.15 | 9.25 | 9.03 |
Support 2 (S2) | 9.05 | 9.20 | 9.06 | 9.00 | |
Support 3 (S3) | 8.87 | 9.05 | 8.97 | ||
Support 4 (S4) | 8.87 |